Cerep SA

Cerep has licensed an LFA-1 receptor antagonist with potential for treating eye disease to Théa for an undisclosed sum. Last year the two firms identified a new topical indication for the antagonist i

Cerep has received an undisclosed milestone payment from Sanofi-Aventis for an antidiabetes drug that the two firms co-discovered in 1998. The NPY1 receptor antagonist is in preclinical development fo

Sales revenues at the French pharmaceutical services firm Cerep were flat during the first half of the year, totalling €14.2 million compared with €14.98 million in the first half of 2007, although at

Better decision making for better drug discovery 4717 Campus Drive Suite 600 Kalamazoo, MI 49008 Phone: (269) 372-3272 Fax: (269) 585-6016 Web Site: www.admetrx.com Contact: Jay Goodwin, President &